Trastuzumab (Herceptin®, Genentech, Inc.), as an anti-HER2 monoclonal antibody, is currently the first-line drug for HER2+ breast cancer, as it significantly improves the chances of cure of early HER2+ breast cancer and reduces the risks of recurrence and death [5, 6]. This evidence concerns the gene ERBB2 and breast carcinoma.